KRKA DD NOVO MESTO
GenericsKRKA DD NOVO MESTO is a generic drug manufacturer focused on Cardiovascular, Neurology.
Upcoming FDA Decisions
Full Calendar →KRKA DD NOVO MESTO's Key Drugs
KRKA DD NOVO MESTO's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
KRKA DD NOVO MESTO's Recent FDA Approvals
New NDA/BLA approvals for KRKA DD NOVO MESTO over the last two years — novel drugs only, excluding generics and label supplements.
KRKA DD NOVO MESTO's Therapeutic Areas
KRKA DD NOVO MESTO's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
KRKA DD NOVO MESTO's Top Competitors
KRKA DD NOVO MESTO's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
KRKA DD NOVO MESTO Pipeline Snapshot
KRKA DD NOVO MESTO has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2000-08-22
- Latest
- 2000-08-22
- Applications
- 2